## **Supplementary Figures**



**Supplementary Figure 1. PLA2G7 is mainly expressed in macrophages in HCC.** (A-C) Analysis of the single data from GSE146115 using the TISCH tool. t-SNE plots for distinct cell subsets (A). t-SNE plot of all single cells colored by the expression level of PLA2G7 (B). Violin plot displaying the expression levels of PLA2G7 in distinct cell subsets (C). (D-F) Analysis of the single data from GSE146409 using the TISCH tool. t-SNE plots for distinct cell subsets (D). t-

SNE plot of all single cells colored by the expression level of PLA2G7 (E). Violin plot displaying the expression levels of PLA2G7 in distinct cell subsets (F). (G-I) Analysis of the single data from GSE125449 using the TISCH tool. t-SNE plots for distinct cell subsets (G). t-SNE plot of all single cells colored by the expression level of PLA2G7 (H). Violin plot displaying the expression levels of PLA2G7 in distinct cell subsets (I). HCC: hepatocellular carcinoma; TISCH: Tumor Immune Single-cell Hu; t-SNE: t-Distributed Stochastic Neighbor Embedding.



Supplementary Figure 2. Multiplex immunofluorescence analysis for PLA2G7, CD68, CD3, and CD20 markers in human HCC tissues. Scale bar: 50 μm.



Supplementary Figure 3. The mRNA levels of PLA2G7 in HCC tissues versus peritumor tissues in TCGA-LIHC and GSE14520 cohorts. Statistical analysis was performed using the Mann-Whitney U test. Data was presented as median with IQR. \*\*\*p<0.001. HCC: hepatocellular carcinoma; TCGA-LIHC, the cancer genome atlas liver hepatocellular carcinoma; IQR: interquartile range.



Supplementary Figure 4. Subgroup analysis on HCC patients with diverse oncogenic etiologies in the Zhongshan cohort. (A) OS curves comparing hepatitis virus-induced HCC and spontaneous HCC (n=115). (B) IHC expression pattern of PLA2G7 in tumor (left panel) or

peritumor (right panel) tissues from hepatitis virus-induced HCC and spontaneous HCC (n=130). (C) OS curves for hepatitis virus-induced (n=97, left panel) or spontaneous (n=18, right panel) HCC patients stratified by low and high expression of PLA2G7. Statistical analysis was performed using the log-rank test in (A) and (C), and the Chi-square test in (B). ns, no significance; \*p<0.05. HCC: hepatocellular carcinoma; OS: overall survival; IHC: immunohistochemistry.



Supplementary Figure 5. The MFI of PLA2G7 and CD68 in tumor tissues from HCC patients with PD and PR. Statistical analysis was performed using the Mann-Whitney U test. Data was presented as median with IQR. \*P<0.05, \*\*p<0.01. MFI: Mean Fluorescence Intensity; HCC: hepatocellular carcinoma; PD: progressive disease; PR: partial response; IQR: interquartile range.



Supplementary Figure 6. PLA2G7 preserves the immunosuppressive phenotype in

**macrophages.** (A) GSEA enrichment analysis of PLA2G7<sup>high</sup> vs. PLA2G7<sup>low</sup> macrophages in Dataset 1. (B-C) Bubble plots showing the expression levels of representative marker genes for proinflammation and T cell activation in PLA2G7<sup>low</sup> and PLA2G7<sup>high</sup> macrophages. GSEA: Gene Set Enrichment Analysis.



**Supplementary Figure 7. Silencing PLA2G7 induces M1 polarization of human macrophages.** (A) Western blot analysis of PLA2G7 in TCM-educated THP-1-differentiated macrophages transfected with control siRNA or siRNA targeting PLA2G7. β-actin was used as loading control. (B) Flow cytometric analysis of CD86 and CD206 on TCM-education THP-1-differentiated macrophages transfected with control siRNA or siRNA targeting PLA2G7. Student's t-test. Data was presented as mean with SD. \*\*p<0.01, \*\*\*p<0.001. TCM: tumor-conditioned media; siRNA: small interfering RNA.



**Supplementary Figure 8. Treatment with Darapladib did not impact the proliferation and migration of human HCC cells.** (A) Cell proliferation in PLC/PRF/5 (left panel) and HCCLM3 (right panel) cells treated with various concentrations of Darapladib was assessed using a CCK-8 assay. (B-D) A wound healing migration assay was performed to evaluate the migration ability of

human HCC cells treated with various concentrations of Darapladib. One-way ANOVA with a post hoc LSD test. Data was presented as mean with SD. ns, no significance. HCC: hepatocellular carcinoma; SD: standard deviation.



Supplementary Figure 9. qPCR analysis of the mRNA levels of immune-regulatory genes in BMDMs. (A) The mRNA levels of immune-regulatory genes in M $\Phi$  (untreated BMDMs) versus TCM-educated BMDMs. (B) The mRNA levels of immune-regulatory genes in TCM-educated BMDMs treated with either Darapladib (0.5  $\mu$ M, 1  $\mu$ M, and 2  $\mu$ M) or vehicle. Statistical analysis was performed using the Student's t-test. Data was presented as mean with SD. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. BMDM: bone marrow-derived macrophage; TCM: tumor condition medium; SD: standard deviation.



Supplementary Figure 10. Flow cytometric analysis of membrane MHC-II on TCM-educated

**BMDMs.** The cells were treated with either Darapladib (2  $\mu$ M), SB203580 (10  $\mu$ M), SB203580 (10  $\mu$ M) + Darapladib (2  $\mu$ M), JSH-23 (10  $\mu$ M), JSH-23 (10  $\mu$ M) + Darapladib (2  $\mu$ M), or vehicle. Representative flow cytometry data (left panel) and the statistical diagram (right panel) are shown. Student's t-test. Data was presented as mean with SD. ns, no significance; \*\*p<0.01, \*\*\*p<0.001. TCM: tumor condition medium; BMDM: bone marrow-derived macrophage; SD: standard deviation; MFI: mean fluorescence intensity.



Supplementary Figure 11. Western blot analysis of p-p38 in macrophages treated with either SB203580 or vehicle.



Supplementary Figure 12. Multiplex immunofluorescence analysis for PLA2G7, F4/80, CD3, and CD20 markers in murine orthotopic HCC tissues. Scale bar: 50 μm.



**Supplementary Figure 13. Multiplex immunofluorescence analysis for PLA2G7 and F4/80 in tumor or peritumor tissues from murine orthotopic HCC.** Representative images and statistical diagram illustrating PLA2G7<sup>high</sup> F4/80<sup>+</sup> cells are shown. Scale bar: 50 μm. Student's t-test. Data was presented as mean with SD. \*\*p<0.01. HCC: hepatocellular carcinoma.



Supplementary Figure 14. Depletion of macrophages abolishes the anti-tumor effects of

**Darapladib.** (A) Representative IHC images depicting F4/80<sup>+</sup> macrophages in murine HCC tumors treated with either vehicle or clodronate liposomes. Scale bar: 100 μm. (B-C) Murine orthotopic HCC treated with either vehicle or Darapladib in control or macrophage-depleted mice. Representative bioluminescence images and statistical diagram illustrating tumor weights are presented (n=5, each). Student's t-test. Data was presented as mean with SD. ns, no significance; \*\*p<0.01. IHC: immunohistochemistry; HCC: hepatocellular carcinoma; SD: standard deviation.

## **Supplementary Tables**

## Table S1. Primers used for quantitative real-time PCR in this study

Name	Forward Sequence (5' to 3')	Reverse Sequence (3' to 5')
β-actin	GGCTGTATTCCCCTCCATCG	CCAGTTGGTAACAATGCCATGT
Arg	CTCCAAGCCAAAGTCCTTAGAG	AGGAGCTGTCATTAGGGACATC
Fizz	CCAATCCAGCTAACTATCCCTCC	ACCCAGTAGCAGTCATCCCA
I110	GCTCTTACTGACTGGCATGAG	CGCAGCTCTAGGAGCATGTG
Il1b	GCAACTGTTCCTGAACTCAACT	ATCTTTTGGGGTCCGTCAACT
I16	TAGTCCTTCCTACCCCAATTTCC	TTGGTCCTTAGCCACTCCTTC
Il12	TGGTTTGCCATCGTTTTGCTG	ACAGGTGAGGTTCACTGTTTCT
Tnfα	CCCTCACACTCAGATCATCTTCT	GCTACGACGTGGGCTACAG

Table	S2.	Antibodies	s used	for	Western	blot	analysis

Antibody	Catalogue number	Company	
Anti-PLA2G7	#15526-1-AP	Proteintech	
Anti-Phospho-Ikkα/β	#2697	Cell Signaling Technology	
Anti-Ikkβ	#2370	Cell Signaling Technology	
Anti-Phospho-NF-κB p65	#3033	Cell Signaling Technology	
Anti-NF-κB p65	#8242	Cell Signaling Technology	
Anti-NF-κB p50	#12540	Cell Signaling Technology	
Anti-Phospho-p44/42 MAPK (Erk1/2)	#4370	Cell Signaling Technology	
Anti-p44/42 MAPK (Erk1/2)	#4695	Cell Signaling Technology	
Anti-Phospho-SAPK/JNK	#4668	Cell Signaling Technology	
Anti-SAPK/JNK	#9252	Cell Signaling Technology	
Anti-Phospho-p38 MAPK	#4511	Cell Signaling Technology	
Anti-p38 MAPK	#8690	Cell Signaling Technology	